Alkem Laboratories Ltd.

NSE: ALKEM · Healthcare

₹5,297.00+2.06%06 Nov 2026

Ask the data

Instant answers about Alkem Laboratories Ltd. — computed from its filings, no language model

Market cap₹63,326 cr

Current price₹5,297.00

High / Low₹5,890 / ₹4,947

P/E29.4

P/B4.58

Book value₹1,156.0

ROE15.6%

ROCE19.7%

Debt / equity0.12

Dividend yield0.97%

EPS (TTM)₹180.47

Face value₹2

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 8 periods

	FY18	FY19	FY20	FY22	FY23	FY24	FY25	FY26
Revenue	6,431	7,357	8,344	10,634	11,599	12,668	12,965	14,712
EBITDA	1,028	1,115	1,473	2,053	1,609	2,245	2,512	3,005
Operating margin	16.0%	15.2%	17.7%	19.3%	13.9%	17.7%	19.4%	20.4%
Interest	55	55	65	52	107	112	122	161
Depreciation	143	193	253	304	310	299	357	382
Profit before tax	926	955	1,260	1,844	1,305	2,023	2,527	2,871
Tax	288	181	110	164	298	212	311	518
Net profit	631	761	1,127	1,646	984	1,796	2,165	2,302
EPS ₹	52.77	63.61	94.26	137.63	82.31	150.19	181.11	192.51
Operating cash flow	—	—	—	1,111	1,682	1,948	1,913	1,963
Capex	—	—	—	339	233	259	676	617
Dividend paid	—	—	—	422	530	540	505	614
Total assets	7,666	8,208	9,946	14,069	13,757	15,575	17,691	20,873
Equity	4,864	5,439	6,161	8,638	9,045	10,312	11,985	13,820

Quarterly performance

last 31 quarters · ₹ crore

showing latest 8 of 31 periods

	MAR '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	JUN '21	SEP '21	DEC '21	MAR '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
Revenue	1,513	1,919	1,925	1,854	1,850	2,264	2,182	2,049	2,003	2,363	2,318	2,731	2,800	2,619	2,484	3,079	3,041	2,903	2,968	3,440	3,324	2,936	3,032	3,415	3,374	3,144	3,371	4,001	3,737	3,603	3,740
Operating profit	114	364	312	235	264	453	453	303	533	600	529	593	624	498	337	454	599	353	389	747	708	402	609	753	759	391	739	921	828	517	766
Operating margin	7.5%	19.0%	16.2%	12.7%	14.3%	20.0%	20.8%	14.8%	26.6%	25.4%	22.8%	21.7%	22.3%	19.0%	13.6%	14.7%	19.7%	12.2%	13.1%	21.7%	21.3%	13.7%	20.1%	22.0%	22.5%	12.4%	21.9%	23.0%	22.2%	14.4%	20.5%
Other income	18	24	9	28	17	31	28	27	44	36	96	47	42	54	21	51	45	69	66	63	94	88	120	134	93	146	136	104	143	200	153
Interest	10	16	15	7	16	18	17	14	17	18	13	13	12	11	17	25	27	29	30	30	25	27	29	28	36	28	30	35	42	54	47
Depreciation	40	46	48	57	56	56	59	81	67	70	69	71	73	77	83	77	78	78	72	74	70	83	80	79	85	112	88	94	95	106	100
Profit before tax	81	326	258	199	210	410	405	235	493	548	543	556	582	464	243	402	539	212	353	648	655	367	619	780	731	396	771	896	781	423	772
Tax	15	66	53	28	23	29	15	44	70	66	80	76	23	-69	134	55	79	144	65	33	51	63	69	78	90	73	103	116	128	171	250
Net profit	67	254	203	167	185	371	382	189	422	472	451	468	544	526	108	331	455	71	287	621	595	294	545	689	626	306	664	765	636	236	520
EPS ₹	5.61	21.28	16.94	14.00	15.51	31.02	31.95	15.79	35.30	39.48	37.72	39.15	45.52	43.96	9.00	27.67	38.03	5.94	23.98	51.90	49.76	24.55	45.60	57.60	52.34	25.57	55.56	63.99	53.19	19.77	43.49
Revenue YoY	—	—	—	22.5%	—	18.0%	13.3%	10.5%	8.3%	4.4%	6.2%	36.3%	18.5%	13.0%	—	10.0%	16.1%	16.9%	—	11.7%	9.3%	1.1%	2.2%	-0.7%	1.5%	7.1%	11.2%	17.2%	10.7%	14.6%	10.9%
Profit YoY	—	—	—	149.5%	—	45.7%	88.6%	12.8%	127.5%	27.3%	18.1%	10.9%	15.3%	16.6%	—	-39.2%	-13.5%	-34.0%	—	87.6%	30.8%	313.6%	90.1%	11.0%	5.2%	4.2%	21.8%	11.1%	1.6%	-22.7%	-21.7%

Earlier results (standalone, Dec '15 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Alkem Laboratories Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

	FY17†
Revenue	4,653
Operating profit	878
Operating margin	18.9%
Other income	117
Interest	24
Depreciation	76
Profit before tax	894
Tax	11
Net profit	883

Quarters

showing latest 8 of 9 periods

	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	1,003	856	1,160	1,327	1,161	1,006	1,127	1,568	1,423
Operating profit	231	84	248	301	221	109	151	442	313
Operating margin	23.0%	9.8%	21.3%	22.6%	19.0%	10.9%	13.4%	28.2%	22.0%
Other income	32	41	33	31	23	30	24	20	23
Interest	14	6	5	7	7	5	8	11	7
Depreciation	18	18	18	19	20	20	23	26	28
Profit before tax	232	100	257	305	217	115	144	426	301
Tax	19	86	6	10	4	-8	32	95	88
Net profit	213	15	251	295	214	123	112	331	213
EPS ₹	17.80	1.21	21.03	24.68	17.87	10.27	9.38	27.66	17.81
Revenue YoY	—	—	—	—	15.7%	17.5%	-2.8%	18.1%	22.6%
Profit YoY	—	—	—	—	0.3%	746.5%	-55.4%	12.1%	-0.3%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 21 periods

	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '22	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
ROE	14.9%	17.0%	20.3%	18.3%	22.1%	23.8%	24.9%	19.1%	12.6%	14.6%	16.0%	17.4%	19.9%	18.5%	18.7%	18.1%	19.1%	17.7%	17.8%	16.7%	15.6%
ROCE	16.5%	17.9%	20.2%	17.1%	20.8%	22.6%	24.3%	16.9%	15.5%	16.8%	17.9%	18.5%	20.8%	19.9%	20.6%	20.3%	21.5%	19.1%	19.5%	19.6%	19.7%
Net margin	10.7%	11.7%	13.6%	13.5%	16.0%	17.0%	17.6%	15.5%	9.5%	11.6%	12.5%	14.2%	16.1%	16.7%	16.9%	16.7%	17.2%	17.0%	16.6%	15.6%	14.3%
EBITDA margin	15.6%	16.0%	17.2%	17.7%	20.5%	22.0%	22.5%	19.3%	15.0%	16.9%	17.4%	17.7%	19.4%	19.4%	19.8%	19.4%	19.9%	20.2%	20.2%	20.4%	20.1%
Debt / equity	0.17	0.17	0.17	0.26	0.26	0.26	0.26	0.30	0.15	0.13	0.13	0.12	0.12	0.11	0.11	0.09	0.09	0.15	0.15	0.12	0.12
Interest coverage	19.22	20.28	22.27	20.36	24.36	26.33	30.17	36.22	14.61	16.09	17.31	19.00	21.49	23.10	21.79	21.76	22.89	22.62	22.02	18.86	17.17
Asset turnover	0.92	0.96	0.99	0.84	0.85	0.86	0.88	0.76	0.87	0.83	0.85	0.81	0.82	0.74	0.75	0.73	0.75	0.68	0.70	0.70	0.72

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 16 periods

	MAR '15‡	MAR '16‡	MAR '17‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26
Share capital	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24	24
Other equity / reserves	2,889	3,668	4,444	4,840	5,415	6,137	7,353	8,614	9,118	9,021	9,819	10,288	11,469	11,961	13,322	13,796
Total equity	2,913	3,692	4,468	4,864	5,439	6,161	7,377	8,638	9,142	9,045	9,842	10,312	11,493	11,985	13,346	13,820
Borrowings	1,162	588	654	892	903	1,577	1,701	2,580	1,836	1,397	1,241	1,214	1,236	1,063	1,962	1,624
Current liabilities	2,006	1,538	1,690	2,383	2,218	3,245	3,604	4,805	3,975	3,707	3,912	3,995	4,171	3,959	4,878	4,783
Non-current liabilities	202	210	295	297	419	392	357	417	527	614	789	866	1,029	1,292	1,599	1,741
Total assets	5,296	5,535	6,568	7,666	8,208	9,946	11,519	14,069	13,869	13,757	14,926	15,575	17,117	17,691	20,287	20,873
Property, plant & equipment	—	1,031	1,394	1,873	2,106	2,306	2,234	2,287	2,257	2,065	2,148	2,161	2,013	2,064	2,111	2,695
Capital work-in-progress	111	172	299	381	493	363	393	339	402	310	181	148	292	477	653	138
Investments	481	509	553	444	324	261	333	371	420	622	626	484	1,160	1,846	2,533	1,869
Inventories	784	909	1,206	1,442	1,500	1,819	2,312	3,006	2,785	2,608	2,541	2,661	2,912	2,922	3,007	3,333
Receivables	527	568	714	1,080	1,248	1,649	1,607	1,885	2,147	2,132	2,448	2,253	2,498	2,466	3,092	2,979
Cash & equivalents	791	127	167	167	249	176	174	232	241	274	321	455	413	304	226	248

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 12 periods

	FY15‡	FY16‡	FY17‡	FY18‡	FY19‡	FY20‡	FY21‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	325	726	471	266	780	585	1,265	1,111	1,682	1,948	1,913	1,963
Cash from investing	-237	202	-286	-357	-316	-741	-999	-1,435	113	-1,009	-1,299	-1,667
Cash from financing	-52	-927	-138	85	-379	79	-272	380	-1,761	-1,145	-811	-503
Capex	138	257	645	684	529	363	195	339	233	259	676	617
Free cash flow	187	469	-174	-418	250	222	1,070	772	1,450	1,689	1,237	1,346
Dividends paid	—	—	—	—	—	—	335	422	530	540	505	614

Where the assets sit

Mar '26 · ₹ crore

Fixed assets (PPE)

₹2,695 cr13%

CWIP

₹138 cr1%

Investments

₹1,869 cr9%

Inventories

₹3,333 cr16%

Receivables

₹2,979 cr14%

Cash & equivalents

₹248 cr1%

Other assets

₹9,611 cr46%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Alkem Laboratories Ltd.	63,326	5,297.00	29.4	4.58	15.6%

StoxGud checklist: Neutral setup · 6/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-1.0%

6 months-5.2%

1 year-4.3%

3Y CAGR+11.5%

5Y CAGR+8.0%

10Y CAGR+13.0%

50-day avg₹5,205.92

200-day avg₹5,429.53

RSI (14)71

Compare Alkem Laboratories Ltd. with

Glenmark Pharmaceuticals vs Alkem Laboratories Alkem Laboratories vs Biocon Alkem Laboratories vs Fortis Healthcare Alkem Laboratories vs Abbott India

FAQs

What is the share price of Alkem Laboratories Ltd.?

Alkem Laboratories Ltd. (ALKEM) closed at ₹5,297.00 on NSE on 06 Nov 2026.

What is the market cap of Alkem Laboratories Ltd.?

₹63,326 crore at the latest close.

What is the P/E ratio of Alkem Laboratories Ltd.?

29.4, on trailing-twelve-month earnings from its filings.

How fast is Alkem Laboratories Ltd. growing?

Alkem Laboratories Ltd.: revenue has compounded at 8.2% a year over three years; net profit at 32.7% a year. Latest-quarter revenue is up 10.9% year on year, profit down 21.7%.

How profitable is Alkem Laboratories Ltd.?

On a trailing-twelve-month basis return on equity is 15.6%, return on capital employed 19.7%, operating margin 20.1%, net margin 14.3%.

How much debt does Alkem Laboratories Ltd. have?

Alkem Laboratories Ltd. is lightly geared: debt to equity is 0.12 with borrowings of ₹1,624 cr against cash of ₹248 cr (balance sheet of 2026-03-31). Operating profit covers interest 17.2 times.

Financials parsed from Alkem Laboratories Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Mar '15. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.